Granulocyte colony-stimulating factor therapy

Mueller BU, Burt R, Gulick L, Jacobsen F, Pizzo PA, Horne M. Disseminated intravascular coagulation associated with granulocyte colony-stimulating factor therapy in a child with human immunodeficiency virus infection. J Pediatr 1995 126(5 Pt l) 749-52. 

Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, Kurtzberg J. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type lb. Blood 2001 97(2) 376-82. 

Melis D, et al. Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type la and with granulocyte colony-stimulating factor therapy in type lb. Horm Paediatr. 2014 81(l) 55-62. 

Abdel-Latif A, Both R, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction a systematic review and metaanalysis of randomized controlled trials. Am Heart J 2008 156(2) 216-226.e9. 

Neutropenia associated with interferon or pegylated interferon therapy is defined as an absolute neutrophil count (ANC) of less than 1000 cells/mm3 in rare cases, an ANC less than 500 cells/mm3 maybe observed. The neutropenia is more common and in some cases more severe with pegylated interferon than with unmodified interferon. Neutropenia usually occurs within the first 2 weeks after initiating either formulation of interferon, with the WBC count stabilizing by week four or six. The neutropenia is reversible upon discontinuing therapy. Granulocyte colony-stimulating factor has been used as an adjunctive therapy for interferon-induced neutropenia in hepatitis patients.44... 

In the next phase of the study, transcripts of up-regulated genes granulocyte colony-stimulating factor (G-CSF) and IgG were introduced into a mouse model corranonly used to test potential therapies for experimental autoimmune encephalomyelitis (EAE). Erom microarray analysis, G-CSF was found to be up-regulated in acute MS but not in the chronic state of the disease. Subcutaneous injection of G-CSF prior to induction of EAE prevented onset of the disease in mice. The reversal of EAE by G-CSE has also been described (see Eock, 2002, Reference 40). 

VokesEE, Haraf DJ, DrinkardLC, etal. A phase I trial of concomitant chemoradio therapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol 1995 35(4) 304-312. 

BrocksteinB, Haraf DJ, Stenson K, etal. Phase I study of concomitant chemoradio therapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998 16 735-744. 

The feasibility and efficacy of granulocyte-colony stimulating factor (G-CSF) therapy and subsequent intracoronary infusion of collected peripheral blood stem cells were prospectively investigated in the MAGIC randomized clinical trial [137], which showed improved cardiac function and promotion of angiogenesis in myocardial infarction patients. 

Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis how has granulocyte colony-stimulating factor changed therapy Thyroid 2005 15(3) 292-7. 

Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol 2001 18(5) 417-21. 

Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988 109(10) 789-95. 

Nishimnra M, Yamada T, Andoh T, Tao T, Emoto M, Ohji T, Matsnda K, Kameda N, Satoh Y, Matsntani A, Aznno Y, Oka Y. Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Int J Hematol 1998 68(2) 203-11. 

Lang E, Cibull ML, Gallicchio VS, Henslee-Downey PJ, Davey DD, Messino MJ, Harder EJ. Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler s syndrome undergoing bone marrow transplantation. Am J Hematol 1992 41(4) 280. ... 

Ishikawa K, Tanaka H, Takaoka M, et al. Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries. J Trauma 1999 46 999-1007. 

MacVittie TJ, Farese A, Herodin F et al. (1996). Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthetic SC-55494 and recombinant human granulocyte-colony stimulating factor. Blood, 97, 4129 1135. 

There is no specific therapy for acute colchicine poisoning. Supportive measures should be used, particularly fluid repletion. Activated charcoal may decrease total colchicine exposure. Hemodialysis does not remove colchicine but may be required as part of supportive care. Colchicine antibodies and the use of granulocyte colony-stimulating factor to treat the leukopenia are under investigation. 

W.J. de Vree, M.C. Essers, J.F. Koster, W. Sluiter (1997). Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res., 57, 2555-2558. 

Schwartz PE et al. (1975) Control of arterial hemorrhage using percutaneous arterial catheter techniques in patients with gynecologic malignancies. Gynecol Oncol 3 276-288 Seidman AD et al. (1993) Dose-intensihcation of MVAC with recombinant granulocyte colony- stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11 408-414... 

---